JP2009525981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525981A5 JP2009525981A5 JP2008553486A JP2008553486A JP2009525981A5 JP 2009525981 A5 JP2009525981 A5 JP 2009525981A5 JP 2008553486 A JP2008553486 A JP 2008553486A JP 2008553486 A JP2008553486 A JP 2008553486A JP 2009525981 A5 JP2009525981 A5 JP 2009525981A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- insufficient
- disease
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 210000003491 Skin Anatomy 0.000 claims 7
- 208000006673 Asthma Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 206010012601 Diabetes mellitus Diseases 0.000 claims 4
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 4
- 206010024324 Leukaemias Diseases 0.000 claims 4
- 206010025135 Lupus erythematosus Diseases 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 4
- 210000002374 Sebum Anatomy 0.000 claims 4
- 206010052779 Transplant rejections Diseases 0.000 claims 4
- 125000004432 carbon atoms Chemical group C* 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 210000000056 organs Anatomy 0.000 claims 4
- 230000028327 secretion Effects 0.000 claims 4
- 230000037067 skin hydration Effects 0.000 claims 4
- 230000037303 wrinkles Effects 0.000 claims 4
- 200000000018 inflammatory disease Diseases 0.000 claims 3
- 201000004681 psoriasis Diseases 0.000 claims 3
- 201000006409 renal osteodystrophy Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 206010009839 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000007442 Ricket Diseases 0.000 claims 1
- 229940046008 Vitamin D Drugs 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 201000001263 psoriatic arthritis Diseases 0.000 claims 1
- 230000000268 renotropic Effects 0.000 claims 1
- -1 t-butyldimethylsilyl groups Chemical group 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
Claims (20)
- X1、X2およびX3がヒドロキシ保護基である、請求項1記載の化合物。
- X1、X2およびX3がt−ブチルジメチルシリル基である、請求項2記載の化合物。
- 有効量の請求項1記載の化合物および薬学的に許容される担体を含む、薬学的組成物。
- 有効量が組成物1グラム当たり化合物約0.01μg〜約1mgを含む、請求項5記載の薬学的組成物。
- 有効量が組成物1グラム当たり化合物約0.1μg〜約500μgを含む、請求項5記載の薬学的組成物。
- 有効量の請求項1記載の化合物を含む、乾癬;白血病;大腸がん;乳がん;前立腺がん;多発性硬化症;狼瘡;糖尿病;宿主対移植片反応;臓器移植の拒絶反応;慢性関節リウマチ、喘息、もしくは炎症性腸疾患から選択される炎症性疾患;しわ、十分な皮膚硬度の不足、十分な皮膚水和作用の不足、もしくは不十分な皮脂分泌から選択される皮膚状態;腎性骨ジストロフィー;または骨粗しょう症から選択される、生物学的状態に苦しむ被験体を処置するための薬学的組成物。
- 生物学的状態が腎性骨ジストロフィー、ビタミンD抵抗性くる病、骨粗しょう症または乾癬性関節炎である、請求項8記載の薬学的組成物。
- 生物学的状態が白血病、大腸がん、乳がん、または前立腺がんから選択される、請求項8記載の薬学的組成物。
- 生物学的状態が多発性硬化症、狼瘡、糖尿病、宿主対移植片反応、または臓器移植の拒絶反応から選択される、請求項8記載の薬学的組成物。
- 生物学的状態が慢性関節リウマチ、喘息、またはセリアック病、潰瘍性大腸炎およびクローン病から選択される炎症性腸疾患から選択される、請求項8記載の薬学的組成物。
- 生物学的状態がしわ、十分な皮膚硬度の不足、十分な皮膚水和作用の不足、または不十分な皮脂分泌から選択される、請求項8記載の薬学的組成物。
- 前記化合物が、被験体に経口的に、非経口的に、経皮的にまたは局所的に投与されるように用いられることを特徴とする、請求項8記載の薬学的組成物。
- 前記化合物が、腹腔内に投与されるように用いられることを特徴とする、請求項8記載の薬学的組成物。
- 前記化合物が、1日当たり0.01μg〜1日当たり1mgの投与量で投与されるように用いられることを特徴とする、請求項8記載の薬学的組成物。
- 乾癬;白血病;大腸がん;乳がん;前立腺がん;多発性硬化症;狼瘡;糖尿病;宿主対移植片反応;臓器移植の拒絶反応;慢性関節リウマチ、喘息、もしくは炎症性腸疾患から選択される炎症性疾患;しわ、十分な皮膚硬度の不足、十分な皮膚水和作用の不足、もしくは不十分な皮脂分泌から選択される皮膚状態;腎性骨ジストロフィー;または骨粗しょう症から選択される生物学的状態の処置のための薬物の調製における、請求項1記載の化合物の使用。
- 有効量の請求項18記載の化合物および薬学的に許容される担体を含む、薬学的組成物。
- 乾癬;白血病;大腸がん;乳がん;前立腺がん;多発性硬化症;狼瘡;糖尿病;宿主対移植片反応;臓器移植の拒絶反応;慢性関節リウマチ、喘息、もしくは炎症性腸疾患から選択される炎症性疾患;しわ、十分な皮膚硬度の不足、十分な皮膚水和作用の不足、もしくは不十分な皮脂分泌から選択される皮膚状態;腎性骨ジストロフィー;または骨粗しょう症から選択される生物学的状態の処置のための薬物の調製における、請求項18記載の化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74321906P | 2006-02-02 | 2006-02-02 | |
US60/743,219 | 2006-02-02 | ||
PCT/US2007/061404 WO2007092721A2 (en) | 2006-02-02 | 2007-01-31 | Vitamin d analog: rak, methods and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009525981A JP2009525981A (ja) | 2009-07-16 |
JP2009525981A5 true JP2009525981A5 (ja) | 2009-11-26 |
JP5113766B2 JP5113766B2 (ja) | 2013-01-09 |
Family
ID=38330725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008553486A Expired - Fee Related JP5113766B2 (ja) | 2006-02-02 | 2007-01-31 | ビタミンd類似体:rak、その方法および使用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7803789B2 (ja) |
EP (1) | EP1984329B1 (ja) |
JP (1) | JP5113766B2 (ja) |
AT (1) | ATE451352T1 (ja) |
AU (1) | AU2007212185B2 (ja) |
CA (1) | CA2637302C (ja) |
DE (1) | DE602007003691D1 (ja) |
ES (1) | ES2339402T3 (ja) |
NZ (1) | NZ569690A (ja) |
WO (1) | WO2007092721A2 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009532458A (ja) * | 2006-04-06 | 2009-09-10 | ウイスコンシン アラムニ リサーチ ファンデーション | 2−メチレン−1α−ヒドロキシ−19,21−ジノルビタミンD3類縁体およびその使用 |
US8193169B2 (en) * | 2006-04-06 | 2012-06-05 | Wisconsin Alumni Research Foundation | (20R)-2α-methyl-19,26,2-trinor-vitamin D analogs |
WO2008125901A2 (en) * | 2006-04-06 | 2008-10-23 | Wisconsin Alumni Research Foundation | 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof |
EP2046737B1 (en) * | 2006-04-06 | 2011-09-07 | Wisconsin Alumni Research Foundation | 2-methylene-1 alpha,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof |
JP2009532460A (ja) * | 2006-04-06 | 2009-09-10 | ウイスコンシン アラムニ リサーチ ファンデーション | 2−置換−1α,25−ジヒドロキシ−19,26,27−トリノルビタミンD類縁体およびその使用 |
AU2007291005A1 (en) * | 2006-04-06 | 2008-03-06 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D analogs with 1,2,or 3,2 heterocyclic ring |
EP2001841B1 (en) * | 2006-04-06 | 2012-06-13 | Wisconsin Alumni Research Foundation | 2-methylene-1 alpha-hydroxy-18,19,21-trinorvitamin d3 analogs and uses thereof |
CA2648521A1 (en) * | 2006-04-10 | 2008-02-28 | Wisconsin Alumni Research Foundation | 1.alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-n0r-vitamin d compounds with a 1,1-dimethylpropyl side chain |
WO2009086438A2 (en) * | 2007-12-28 | 2009-07-09 | Wisconsin Alumni Research Foundation | 2-methylene-(20s,25r)-19,26-dinor-vitamin d analogs |
US7947666B2 (en) * | 2007-12-28 | 2011-05-24 | Wisconsin Alumni Research Foundation | 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs |
US8193170B2 (en) | 2008-07-10 | 2012-06-05 | Wisconsin Alumni Research Foundation | 2-methylene-19,26-dinor-(20R,22E,25R)-vitamin D analogs |
US7648974B1 (en) * | 2008-07-10 | 2010-01-19 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D analogs with 3,2-dihydrofuran ring |
US7879829B2 (en) * | 2008-07-10 | 2011-02-01 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D analogs with 1,2-dihydrofuran ring |
US8399439B2 (en) * | 2008-07-10 | 2013-03-19 | Wisconsin Alumni Research Foundation | 2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs |
US8217023B2 (en) | 2009-10-02 | 2012-07-10 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D analogs with 1,2- or 3,2-cyclopentene ring |
MX2012003883A (es) | 2009-10-02 | 2012-06-27 | Wisconsin Alumni Res Found | Analogos de (20s,22e)-2-metileno-19-nor-22-ene-1a,25-dihidroxovita mina d3. |
US8404874B2 (en) * | 2010-09-30 | 2013-03-26 | Wisconsin Alumni Research Foundation | (20R,25S)-2-Methylene-19,26-Dinor-1α,25-Dihydroxyvitamin D3 in crystalline form |
AU2012271759B2 (en) * | 2011-06-14 | 2017-02-02 | Wisconsin Alumni Research Foundation | 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666634A (en) | 1984-12-05 | 1987-05-19 | Chugai Seiyaku Kabushiki Kaisha | vitamin D3 derivatives having a substituent at 2-position |
US5086191A (en) | 1991-05-28 | 1992-02-04 | Wisconsin Alumni Research Foundation | Intermediates for the synthesis of 19-nor vitamin D compounds |
DE69400495T2 (de) | 1993-04-05 | 1997-04-30 | Wisconsin Alumni Res Found | 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle |
US5552392A (en) | 1993-11-03 | 1996-09-03 | Wisconsin Alumni Research Foundation | Method of treating hypoparathyroidism with (20S) vitamin D compounds |
US6306844B1 (en) * | 1997-03-17 | 2001-10-23 | Wisconsin Alumni Research Foundation | Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength |
US6392071B1 (en) | 1997-03-17 | 2002-05-21 | Wisconsin Alumni: Research Foundation | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds |
US5945410A (en) | 1997-03-17 | 1999-08-31 | Wisconsin Alumni Research Foundation | 2-alkyl-19-nor-vitamin D compounds |
US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
DK1286962T3 (da) | 2000-05-31 | 2008-10-06 | Wisconsin Alumni Res Found | 2-Ethyl og 2-ethyliden-19-nor-vitamin D-forbindelser |
US6440953B1 (en) | 2000-09-08 | 2002-08-27 | Wisconsin Alumni Research Foundation | 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses |
EP1392323B1 (en) | 2001-05-22 | 2008-10-08 | Bioxell S.p.a. | Use of a vitamin d3 analogue for the treatment of autoimmune diabetes |
US6627622B2 (en) | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
US6566352B1 (en) | 2002-02-18 | 2003-05-20 | Wisconsin Alumni Research Foudation | 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
US20030195175A1 (en) * | 2002-03-25 | 2003-10-16 | Deluca Hector F. | Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone |
GB0305332D0 (en) | 2003-03-10 | 2003-04-09 | Leuven K U Res & Dev | Biological evaluation of novel vitamin D analogues |
US6894037B2 (en) * | 2003-07-03 | 2005-05-17 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses |
US20050009792A1 (en) | 2003-07-08 | 2005-01-13 | Deluca Hector F. | (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses |
KR20060040746A (ko) | 2003-09-19 | 2006-05-10 | 화이자 프로덕츠 인크. | 2-알킬리덴-19-노르-비타민 d 유도체와 에스트로겐효능제/길항제의 조합물을 포함하는 제약 조성물 및 방법 |
US7053075B2 (en) | 2003-11-25 | 2006-05-30 | Deluca Hector F | Methods for reducing body fat using vitamin D compounds |
JP2007512376A (ja) | 2003-11-25 | 2007-05-17 | ウイスコンシン アラムニ リサーチ ファンデーション | 肥満症の予防及び治療用ビタミンd類似体 |
WO2006057884A2 (en) * | 2004-11-22 | 2006-06-01 | Wisconsin Alumni Research Foundation | 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES |
US7235680B2 (en) * | 2005-03-29 | 2007-06-26 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone |
JP2008542201A (ja) | 2005-05-03 | 2008-11-27 | ウイスコンシン アラムニ リサーチ ファンデーション | 19,26,27−トリノル−1α,25−ジヒドロキシビタミンD3化合物 |
US7528122B2 (en) * | 2006-02-02 | 2009-05-05 | Wisconsin Alumni Research Foundation | Vitamin D analog—NEL, methods and uses thereof |
JP2009532458A (ja) | 2006-04-06 | 2009-09-10 | ウイスコンシン アラムニ リサーチ ファンデーション | 2−メチレン−1α−ヒドロキシ−19,21−ジノルビタミンD3類縁体およびその使用 |
-
2007
- 2007-01-30 US US11/669,053 patent/US7803789B2/en not_active Expired - Fee Related
- 2007-01-31 CA CA2637302A patent/CA2637302C/en not_active Expired - Fee Related
- 2007-01-31 AU AU2007212185A patent/AU2007212185B2/en not_active Ceased
- 2007-01-31 WO PCT/US2007/061404 patent/WO2007092721A2/en active Application Filing
- 2007-01-31 EP EP07763622A patent/EP1984329B1/en not_active Not-in-force
- 2007-01-31 JP JP2008553486A patent/JP5113766B2/ja not_active Expired - Fee Related
- 2007-01-31 ES ES07763622T patent/ES2339402T3/es active Active
- 2007-01-31 DE DE602007003691T patent/DE602007003691D1/de active Active
- 2007-01-31 AT AT07763622T patent/ATE451352T1/de not_active IP Right Cessation
- 2007-01-31 NZ NZ569690A patent/NZ569690A/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009525981A5 (ja) | ||
CA2597624A1 (en) | 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2 | |
JP2010505739A5 (ja) | ||
JP2009532458A5 (ja) | ||
JP2008520703A5 (ja) | ||
JP2008520690A5 (ja) | ||
JP2007512376A5 (ja) | ||
CN1140509C (zh) | 新的维生素d类似物 | |
JP2008520705A5 (ja) | ||
WO2006009092A1 (ja) | 効果的な医薬の使用法及び副作用発現の防御に関する方法 | |
JP2008520704A5 (ja) | ||
JP2007526331A5 (ja) | ||
JP2008530109A5 (ja) | ||
JP2009536191A5 (ja) | ||
JP2013541503A5 (ja) | ||
JP2013522369A5 (ja) | ||
JP2007502832A5 (ja) | ||
JP2009185034A5 (ja) | ||
AU2021215137A1 (en) | Androgen receptor modulators and methods for their use | |
JP2008520716A5 (ja) | ||
JP2019534865A5 (ja) | ||
KR20060012032A (ko) | 혈청 콜레스테롤 저하제 또는 아테롬성 동맥경화증의 예방또는 치료제 | |
JP2006523239A5 (ja) | ||
JP2006510658A5 (ja) | ||
NZ570711A (en) | 2-Substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof |